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Inducible Transgenic Mice Reveal
Resting Dendritic Cells as Potent Inducers
of CD8 T Cell Tolerance
tion of costimulatory molecules, such as CD86 as well
as MHC class I and II molecules (Banchereau and
Steinman, 1998; Cella et al., 1997), all contributing to an
efficient priming of naive T cells. There is ample evidence
that antigen presentation by activated DC is required
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and sufficient for the induction of T cell responses inSwitzerland
vivo. Conditional depletion of CD11C DC in vivo re-2 Institute for Immunology
sulted in complete absence of CTL priming after infec-Biomedical Research Centre Alexander Fleming
tion with Listeria monocytogenes or with Plasmodium16672-Vari
yoelii (Jung et al., 2002), identifying DC as the only APCGreece
being able to prime naive CTL.
Bone marrow-derived antigen-bearing DC matured in
vitro have been shown to induce specific T cell re-Summary
sponses upon adoptive transfer (Banchereau and
Steinman, 1998; Bennett et al., 1998; Dhodapkar et al.,Dendritic cells (DC) are inducers of immune responses
1999; Diehl et al., 1999; Inaba et al., 1993; Schoenbergerpar excellence. They also seem responsible for the
et al., 1998; Schuurhuis et al., 2000; Sotomayor et al.,induction of peripheral T cell tolerance. To investigate
1999). Evidence for induction of immunity as the majorthese opposite functions of DC, we generated a Cre/
function of DC is mostly based on experiments thatLoxP-based system that allows inducible antigen pre-
involved DC purification or culture in vitro, which aresentation by DC in vivo. This enables us to study the
known to dramatically change the phenotype and immu-immunogical consequences of antigen presentation
nostimulatory capacities of DC (Gallucci et al., 1999;by resting versus mature DC without adoptively trans-
Pierre et al., 1997). Thus, the effect on naive T cells offerring DC and with physiological numbers of endoge-
antigen presentation by DC in noninflammatory, steady-nous, naive responder T cells. We found that presenta-
state situations was difficult to study using adoptivelytion of LCMV-derived CTL epitopes by resting DC
transferred DC. Nevertheless, it was found that adop-resulted in antigen-specific tolerance, which could not
tively transferred, freshly isolated, and antigen-pulsedbe broken by subsequent infection with LCMV. On
resting human DC induced silencing or inhibition of anti-the other hand, antigen presentation by activated DC
gen-specific CD8 T cell effector functions in a limitedprimed endogenous CTL to expand and to develop
number of healthy human recipients (Dhodapkar andprotective effector function.
Steinman, 2002; Dhodapkar et al., 2001). In vivo tar-
geting of antigen to DEC205 DC resulted in abortiveIntroduction
proliferation of adoptively transferred TCR transgenic
CD4 T cells (Hawiger et al., 2001) and of CD8 T cellsThe induction of an efficient and protective adaptive
(Bonifaz et al., 2002). In addition, autoantigen presentedimmune response depends on the interaction between
by CD11cCD8CD4 DC has been shown to mediatenaive antigen-specific T lymphocytes and professional
suppression of autoimmunity in vivo (Legge et al., 2002).antigen-presenting cells (APC). Because of their unique
Using adoptively transferred TCR transgenic T cells asfeatures, such as migratory capacity and expression of
a read out, antigen presentation of tissue-specific anti-costimulatory molecules and major histocompatibility
gens by bone marrow-derived APC, that were identified
complex (MHC) molecules, dendritic cells (DC) are con-
as CD11cCD8 DC, was demonstrated under steady-
sidered the prototype of professional APC. DC are pres-
state conditions in draining lymph nodes. This induced
ent as sentinels in peripheral tissues, where they can abortive activation of the responding T cells, resulting
capture antigens that may be processed and presented in tolerance (Belz et al., 2002; Hernandez et al., 2001;
to CD4 and CD8 T cells. Most DC in peripheral tissues Kreuwel et al., 2002; Kurts et al., 1997; Liu et al., 2002;
have a resting phenotype: They can efficiently take up Scheinecker et al., 2002). In contrast, in vivo targeting
antigens but do not present these productively to naive of SIINFEKL to CD11cCD11bCD8 DC was found
T cells (Banchereau and Steinman, 1998; Inaba et al., to prime naive, endogenous CTL (Guermonprez et al.,
1993). After interaction with products of microbial or 2002). These conflicting data may be due to the use of
viral pathogens (LPS, dsRNA, CpG DNA) through one different experimental systems, such as the analysis of
or more members of the family of Toll-like receptors transferred versus endogenous T cells, the frequency
(TLR) (Kaisho and Akira, 2001), with proinflammatory of naive responder T cells, or to different means of tar-
cytokines (TNF, IL-1) or after ligation of surface CD40 geting of the antigen to DC in vivo, thereby “touching”
(Bennett et al., 1998; Schoenberger et al., 1998), DC one of their surface molecules.
acquire an activated phenotype. Activated DC change Most experiments addressing the issue of tolerance
their expression pattern of homing receptors, allowing induction by resting DC relied on adoptively transferred,
efficient migration into T cells zones of lymph nodes TCR transgenic T cells as a read out, which results in
(Roake et al., 1995; Sallusto et al., 1998) and upregula- abnormally high precursor frequencies. This is particu-
larly disturbing as it has been shown that CD8 T cells
can activate DC (Ruedl et al., 1999) or provide their own*Correspondence: maries@pathol.unizh.ch
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help (Wang et al., 2001), given that their frequency is
sufficiently high. More important, the outcome of antigen
presentation on naive DC was found to vary dramatically
with the number of TCR transgenic T cells transferred.
Adoptive transfer of low numbers of TCR transgenic
T cells specific for ovalbumin (OVA) or for influenza virus-
derived heamagglutininin (HA) into mice expressing OVA
or HA under control of the rat insulin promoter (RIP)
Figure 1. Generation of DIETER (ST33.396 X CD11cCreERT) Trans-resulted in initial activation of the TCR transgenic T cells,
genic Mice
followed by complete tolerance induction. However, tol-
DIETER mice are double transgenic offspring of CD11cCreERT Xerance induction was less efficient at higher frequencies
ST33.396 mice and therefore carry two transgenic constructs: (1)
of specific T cells (Kurts et al., 1997; Morgan et al., Cre recombinase as a fusion protein with the mutated hormone
1999), and if precursor frequencies were even further binding domain of the human estrogen receptor (ER) under control
of the DC-specific CD11c promoter. In absence of ER ligand, Creincreased, tolerization of autoagressive T cells reverted
recombinase is associated with heat shock proteins, which inhibitto their activation, resulting in autoimmunity (Kurts et
translocation of Cre into the nucleus. After association of ER withal., 1997; Morgan et al., 1996).
(synthetic) ligand (Tamoxifen), Cre can translocate into the nucleusTo circumvent problems mentioned above, we devel-
and remove loxP-flanked nucleotides. (2) A transgene encoding
oped an approach that allows direct in vivo comparison LCMV-derived CTL epitopes (GP33-41/Db and NP396-404/Db) and
of resting DC and activated DC for their respective ca- an E. coli -galactosidase-derived CTL epitope (Gal497-505/Kb) as
a fusion protein with enhanced green fluorescent protein (eGFP).pacity to prime, to be ignored by, or to tolerize naive
The transgene is separated from its ubiquitous chicken -actin pro-CD8 T cells without the need for adoptive transfers of
moter by a loxP-flanked STOP cassette, which prevents expressiondendritic cells or of responding T cells, or other manipu-
of the transgene. Thus, DIETER mice only express the transgene,lations that might disturb the steady-state situation in an
resulting in the presentation of transgenic CTL epitopes by CD11c
immunocompetent mouse. Our system uses inducible cells (DC), after administration of Tamoxifen.
expression and presentation of lymphocytic choriomen-
ingitis virus (LCMV)-derived CTL epitopes by resting DC
or by activated DC in vivo. We are able to induce a small After injection of 2 mg TAM, 4%–8% of CD11c in
percentage of all CD11c DC to present transgenic CTL spleen, lymph nodes, and thymus were found to express
epitopes in thymus, lymph nodes, and spleen. We ob- Cre activity (Figure 2C). No green fluorescence was de-
served that activated, antigen-presenting DC efficiently tected in non-CD11c cells (Figure 2A) or in CD11c
primed naive, endogenous CTL to proliferate and to cells without TAM injection (Figure 2C). The percentage
differentiate into protective effectors, whereas resting, of CD11c cells presenting the transgene is in a physio-
antigen-presenting DC induced antigen-specific toler- logical range, as around 8% of splenic CD11c cells
ance, that could not be broken by a subsequent infection stain positive for LCMV-NP at 2 days after infection with
with LCMV. LCMV (data not shown).
Antigen Presentation by Activated DC in DIETER MiceResults and Discussion
Primes Endogenous, Naive CD8 Cells
DIETER mice were injected with 2 mg TAM (to induceGeneration and Characterization of CD11cCreERT,
ST33.396, and (CD11cCreERT X ST33.396) Cre activity resulting in presentation of GP33, NP396,
and Gal497 by CD11c cells in vivo), with 30 g anti-(DIETER) Mice
DIETER mice are double transgenic offspring of CD40 (to activate DC in vivo), with 2 mg TAM plus 30
g anti-CD40, or were left untreated. Staining of spleno-(CD11cCreERT X ST33.396) breeding and express induc-
ible Cre recombinase in CD11c cells as a transgene. cytes for CD11c/CD86, CD11c/I-Ab, and CD11c/CD54
at different time points after injection of 30 g anti-Cre activity is induced by a single i.p. injection of 2 mg
tamoxifen (TAM), which results in the presentation of CD40 followed by FACS analysis showed that all three
markers, which are characteristic for activated DC, weretransgenic CTL epitopes by DC (Figure 1). Injection of
DIETER mice with TAM together with an agonistic anti- 3- to 6-fold upregulated with a maximum at 24–36 hr
after injection of anti-CD40 (data not shown), thus con-CD40 antibody leads to presentation of transgenic CTL
by activated DC; administration of TAM alone leads to firming previously published data (Hawiger et al., 2001).
The number of GP33-, NP396-, and Gal497-specificantigen presentation by resting DC.
Because we were unable to detect green fluorescence CD8 T cells was quantified 7 days after the injections
by tetramer staining of blood leukocytes. Injection ofin CD11c cells of DIETER mice after deletion of the
STOP cassette, probably due to instability of the fusion DIETER mice with TAManti-CD40 primed naive, en-
dogenous CD8 cells to expand substantially: aroundprotein, we bred CD11cCreERT mice with eGFP-based
Cre-indicator mice (RAGE%) (Constien et al., 2001) and 15% of the CD8 cells were found to be GP33 specific,
1% were NP396 specific, and 7% were Gal497 specificinjected the F1 mice with TAM. We detected Cre activity
as measured by green fluorescence exclusively in (Figure 3A). Naive endogenous CD8 T cells did not
expand to detectable levels after injection of DIETERCD11c cells (Figure 2A). Next, we isolated CD11c cells
from spleens of (RAGE% X CD11cCreERT) F1 40 hr after mice with TAM or anti-CD40 alone (Figure 3A) or after
injection of C57BL/6 mice with any of the combinationsadministration of 2 mg TAM and stained these with
CD8-APC/CD4-PE. We found Cre activity in all major mentioned above (data not shown). No expansion was
found in control groups at d 9 (data not shown). To testsubsets of splenic DC upon TAM injection (Figure 2B).
Inducible Transgene Expression in Dendritic Cells
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Figure 2. Characterization of CD11cCreERT
Mice
(A) Using RAGE% mice as indicator, Cre ac-
tivity can be visualized by green fluores-
cencent protein expression. (CD11cCreERT X
RAGE%)F1 mice were injected i.p. with 2 mg
TAM, and 40 hr later splenocytes were
stained with anti-CD11c-PE to identify DC.
(B) CD11c cells were MACS-purified from
spleen 40 hr after administration of 2 mg TAM.
CD11c cells were stained with anti-CD4-PE
and anti-CD8-APC. Green fluorescence was
detected in all subsets of DC. This experiment
is one out of three comparable experiments.
(C) Quantification of the number of CD11c
cells with Cre activity. (CD11cCreERT X
RAGE%)F1 mice were injected i.p. with 2 mg
TAM (solid bars) or solvent (open bars), and
cells from thymus, mesenteric lymph nodes,
and spleen were stained for CD11c-PE 40 hr
later. The percentage of CD11c cells with
Cre activity is shown as the mean  SD of
three mice.
for antiviral protective effector function, the same mice two of which (GP33, NP396) are presented by DIETER
DC after TAM injection. We found greatly reduced GP33-were challenged with LCMV and viral titers were deter-
mined in spleen 4 days thereafter. High LCMV titers were and NP396-specific CTL in TAM-treated, LCMV-infected
DIETER mice compared with solvent-treated mice (Fig-found in nontransgenic C57BL/6 mice as well as in those
DIETER mice that were injected with TAM or with anti- ure 4A), but a normal GP276 response. The difference
between TAM- and solvent-treated DIETER mice wasCD40 or that were untreated). No virus was found in
DIETER mice previously injected with TAManti-CD40 even more pronounced in ICS (Figure 4B). This shows
that antigen presentation by resting DC resulted in toler-(Figure 3B). This shows that only activated, antigen-
presenting DC prime naive, endogenous CTL to expand ance of specific CD8 T cells, which could not be broken
by subsequent infection with LCMV. Importantly, we(Figure 3A) and to acquire effector functions in vivo (Fig-
ure 3B). To exclude the contribution of a direct effect found that LCMV infection primed GP276-specific CTL
in TAM-treated DIETER mice to a degree comparableof anti-CD40 on CD8 T cells (Bourgeois et al., 2002),
we injected DIETER mice with 2 mg TAM i.p. and acti- to that found in the three control groups (solvent-treated
DIETER in Figure 4B; solvent- or TAM-treated C57BL/6vated DC with 250 g poly-IC i.v. Like after injection of
2 mg TAM  30 g anti-CD40, we found priming of not shown). Stimulation of splenocytes by PMA/Iono-
mycin resulted in similar percentages of IFN-producingendogenous, transgene-specific CD8 T cells (data not
shown). Moreover, adoptively transferred, mature bone CD8T cells in TAM-treated and in control DIETER mice,
suggesting that the total number of LCMV-specific CTLmarrow-derived DC isolated from (ST33.396 X Deleter)
mice efficiently primed GP33-, NP396-, and Gal497- primed by infection was similar: CTL specific for domi-
nant and subdominant epitopes other than GP33 andspecific, endogenous CTL in C57BL/6 mice (data not
shown) without the need for anti-CD40 injection. Deleter NP396 may compensate for the tolerized CTL popula-
tions. Priming of small numbers of GP33- or NP396-mice express Cre recombinase in a ubiquitous and con-
stitutive fashion. specific CTL or partial priming by resting DC could be
excluded, because in vitro restimulation with relevant
peptides did not result in substantial CTL activity (FigureAntigen Presentation by Resting DC in DIETER Mice
Induces Peripheral, Antigen-Specific Tolerance 3C). The fact that GP276-CTL were efficiently primed
and that the total number of LCMV-specific CTL wasTo analyze whether antigen presentation by resting DC
resulted in ignorance or in peripheral tolerance, we in- normal clearly shows that tolerance induced by antigen-
presenting resting DC was an antigen-specific phenom-jected DIETER mice with 2 mg TAM. This treatment did
not result in detectable priming of naive CD8 T cells enon and was not due to transgenic artifacts resulting
in defective antigen-presenting cells. DIETER DC didas determined by tetramer stains on d 5 (not shown)
and on d 7 (Figure 3A). As control, we injected DIETER not present helper epitopes upon induction with TAM;
therefore, we cannot conclude from our data whethermice with solvent. On d 7, mice were infected with 100
pfu LCMV-Arm. Priming by LCMV was analyzed 12 days additional and simultaneous presentation of helper epi-
topes by resting DC would affect the outcome of CD8after infection by tetramer staining, by intracellular stain-
ing for interferon (ICS), and by a CTL assay after restim- T cell tolerance. However, based on the findings of Hawi-
ger et al. (2001), we expect also that CD4 T cells wouldulation with the relevant peptide in vitro. LCMV infection
of C57BL/6 (H-2b) mice induces CTL specific for three be tolerized and that thus CD8 T cell tolerance would
be unaffected.immunodominant epitopes: GP33, GP276, and NP396,
Immunity
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Figure 4. Antigen Presentation by Resting DC Induces Antigen-
Specific Tolerance of Endogenous CD8 Cells
DIETER mice were injected i.p. with 2 mg TAM (closed symbols) or
with solvent (open symbols) on d 7. They were infected i.v. with
Figure 3. Antigen Presentation by Activated DC Induces Antigen- 102 pfu LCMV-Armstrong on d 0, and the LCMV-induced CTL re-
Specific Priming for Expansion and for Protective Immunity of En- sponse was measured in the spleen on d 12 by tetramer staining
dogenous CD8 Cells (A), by ICS (B), and by a cytotoxicity assay after restimulation in
vitro (C). Lysis of EL-4 targets without peptide was 	15% of theDIETER mice were injected on d 8 with 30 g anti-CD40 i.v. (to
specific lysis. Spontaneous lysis of targets was 	15%. One repre-activate DC), with 2 mg TAM i.p. (to induce presentation of CTL
sentative experiment out of four is shown. Symbols or curves repre-epitopes by DC), or with 30 g anti-CD40 i.v.  2 mg TAM i.p.
sent the values of individual mice.(A) On d1, blood leukocytes were stained with tetramers to detect
expansion of transgene-specific CTL. Staining from one representa-
tive mouse out of four is shown. Values in the upper right quadrant
is presumably more efficient than crosspresentationrepresent the mean (/ SD) percentage of tetramer cells within
CD8 cells. (Morgan et al., 1999; Scheinecker et al., 2002).
(B) Mice were challenged on day 0 with 100 pfu LCMV-Armstrong, It has been described that, besides in DC, the CD11c
and viral titers were determined in spleens at d 4 using a focus- promoter is also active in a certain percentage of acti-
forming assay. One representative experiment of two is shown; val-
vated T cells and intraepithelial lymphocytes (Huleattues represent the titers of individual mice. The broken line repre-
and Lefrancois, 1995; Jung et al., 2002). To excludesents the detection limit of the assay.
that CD8 T cell tolerance described by us was due
to antigen presentation by CD8 T cells followed by
“fratricide” rather than to antigen presented by restingOur data show that tolerance induced by resting DC
is robust, as it could not be broken by a subsequent DC, we performed the following control experiment. DIE-
TER (Thy1.2)C57BL/6.PL (Thy1.1)→C57BL/6 (Thy1.2)infection with LCMV, which is known to very efficiently
prime CTL responses. It has been shown in other sys- bone marrow chimeras were injected with 2 mg TAM or
with solvent on d 0 and were challenged with 100 pfutems (Morgan et al., 1999; Scheinecker et al., 2002) that
tolerance induced by resting DC that continuously LCMV-Armstrong on d 7. The CTL response was ana-
lyzed on d 12 after LCMV challenge (see also Figure 4).crosspresent (neo)self-antigens is more limited in nature
compared with tolerance in DIETER mice. The complete- We found a strong LCMV-specific CTL response against
GP33, GP276, and NP396 in solvent-treated, mixed chi-ness of tolerance seemed to depend on the ratio be-
tween the number of autoreactive precursors and the meras in both the Thy1.1 (Figure 5) and the Thy1.2
(data not shown) CD8 cells as measured by tetramernumber of tolerizing DC (Morgan et al., 1999). We think
that DIETER mice display such a robust tolerance, be- (Figure 5A) and by ICS (Figure 5B). More important, we
found that the response against the two epitopes pres-cause the relatively high number of tolerizing DC
(4%–8% of all CD11c cells, Figure 2) compared with ent in DIETER mice (GP33, NP396) was equally de-
pressed in the Thy1.1 (Figure 5) and the Thy1.2 (notthe limited number of endogenous T cell precursors
(Blattman et al., 2002). In addition, direct presentation shown) populations in TAM-treated, mixed chimeras,
whereas the GP276-specific CTL response was inducedof intracellular antigen, as is the case in DIETER mice,
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without targeting of antigens to DC, and with physiologi-
cal frequencies of endogenous, naive responder T cells,
that DC mediate two completely opposite functions in
the immune response, one being the induction of func-
tional immunity and the other the induction of peripheral
tolerance. The immunological outcome was found to
depend solely on the activation status of the antigen-
presenting DC. Using a novel and versatile system that
allows inducible expression of CTL epitopes on a cell
type of choice, we showed that antigen presented by a
small percentage of all CD11c DC in activated condi-
tion was sufficient to prime naive, endogenous CTL to
expand and to develop effector functions, and that the
Figure 5. Tolerance Is Not Due to Promiscuous CD11c Promoter
very same DC in a resting status induced robust periph-Activity Resulting in Fratricide
eral CD8 T cell tolerance. We showed that this periph-DIETER (Thy1.2)  C57BL/6.PL (Thy1.1) → C57BL/6 (Thy1.2) bone
eral tolerance is antigen specific, is not due to abnormal-marrow chimeras were treated with 2 mg TAM or with solvent on d
ities in the DC compartment, and cannot be broken by7 and were infected with 100 pfu LCMV-Armstrong on d 0, and
the LCMV-specific CTL response was analyzed on d 12 by tetramer a strong stimulus, such as infection with a replicating
staining (A) and by ICS (B). Each group contained three mice. virus, or restimulation in vitro.
Experimental Proceduresnormally. If depressed responses in TAM-treated DIE-
TER mice would have resulted from CD8-mediated frat-
Generation of DIETER Transgenic Mice
ricide, GP33- and NP396-specific responses should DIETER mice are double transgenic offspring of a crossing of
have been absent from the Thy1.2 population only. The ST33.396 transgenic mice with CD11cCreERT transgenic mice.
fact that these responses were found to be absent from CD11cCreERT mice express Cre recombinase as a fusion protein
with the mutated hormone binding domain of the human estrogentransgenic (Thy1.2, not shown) as well as from nontrans-
receptor under control of the murine CD11c promoter (Brocker etgenic (Thy1.1) populations clearly shows that the phe-
al., 1997; Feil et al., 1996). In absence of ligand, Cre recombinasenomenon we observed is genuine T cell tolerance medi-
is associated with heat shock proteins, which inhibit translocation
ated by antigen presentation by resting DC in vivo. into the nucleus. After injection of ligand (Tamoxifen), Cre can trans-
We did not find proliferation of endogenous naive CTL locate into the nucleus and remove loxP-flanked nucleotides.
precursors as a result of antigen presentation by resting CD11cCreERT mice were generated by injecting the 8.6 kb NotI-SalI
fragment of pCD11cCreERT into the pronuclei of fertilized C57BL/6DC. This is in contrast with data published by others
oocytes. pCD11cCreERT was constructed by cloning the 2 kb EcoRI(Belz et al., 2002; Bonifaz et al., 2002; Hawiger et al.,
fragment of pCreERT (Feil et al., 1996) into the EcoRI site of the2001; Hernandez et al., 2001; Kreuwel et al., 2002; Kurts
plasmid CD11c.pDOI-5 (Brocker et al., 1997).
et al., 1997; Liu et al., 2002; Scheinecker et al., 2002), ST33.396 mice express a fusion protein of three CTL epitopes
who always used adoptively transferred TCR transgenic and eGFP under control of the ubiquitous chicken -actin promoter
T cells as responders. This discrepancy may be explained (Ludin et al., 1996). To allow inducible expression of the transgene,
a loxP-flanked STOP cassette (Sauer, 1993) was cloned betweenby differences in responding precursor frequencies: up
the promoter and the transgene. ST33.396 mice were generatedto 106 per mouse after adoptive transfer of TCR trans-
by injecting the 6.5 kb NdeI-KpnI fragment from p-actinST33.396genic cells, and about 100 per mouse (Blattman et al.,
into fertilized C57BL/6 oocytes. To generate p-actinST33.396, a
2002) in our experiments. We decided not to use adop- 276 bp PCR fragment encoding aa 1–80 of the LCMV glycoprotein,
tive transfers, to assure that the steady-state situation which include the immunodominant, H-2Db-restricted CTL epitope
was not disturbed and, more importantly, to be able to GP33-41 (van der Most et al., 1996), was cloned into the EcoRI
site of the vector peGFP-N2 (Clontech Laboratories, Palo Alto, CA).study endogenous, polyclonal T cells. It is the conse-
Sequences encoding two further CTL epitopes, the H-2Db-quence of this approach, that we cannot conclude from
restricted, LCMV nucleoprotein-derived NP396-404 (van der Mostour data whether or to what extent tolerance induction
et al., 1996) and the H-2Kb-restricted, -galactosidase-derived
of T cells present at physiological precursor frequencies
Gal497-504 (Oukka et al., 1996) were introduced as synthetic oligo-
was preceded by abortive T cell activation or prolifera- nucleotides (396.497.1 and 396.497.2) into the SpeI/ApaI-digested
tion. At present, it is unclear by which mechanism imma- construct between the LCMV-GP fragment and eGFP, in frame
with both. To facilitate processing of transgenic CTL epitopes, theyture DC induce peripheral tolerance, nor is it clear whether
were flanked by one aa from their original context. The resultingonly naive or also effector or memory T cells can be
construct, pCMV33.396.497eGFP, encodes a fusion protein of viraltolerized by immature DC. It has been shown that inter-
and bacterial sequences with eGFP. To allow inducible expression
action of T cells with antigen-presenting, immature DC of this fusion protein, a LoxP-flanked STOP cassette (Sauer, 1993)
results in abortive proliferation followed by deletion of was cloned as a 1.6 kb blunted NotI fragment into the blunted HindIII
the T cells (Hawiger et al., 2001; Kurts et al., 1997). site of pCMV33.396.497eGFP, located in the multiple cloning site 5

to the coding sequences. The resulting plasmid, pCMVSTOPL33.396.However, other studies demonstrated that immature
497eGFP, was digested with NotI, blunted, and digested with NheI(Dhodapkar et al., 2001; Dhodapkar and Steinman, 2002;
and the 2.7.kb fragment containing the protein coding sequences,Hugues et al., 2002) or partially mature (Menges et al.,
and the loxP-flanked STOP cassette was introduced into the MamI/
2002; King et al., 2001) DC induce regulatory T cells that SpeI-digested plasmid pactin16 (Ludin et al., 1996).
suppress T cell function by IL-10 (Dhodapkar et al., 2001;
Dhodapkar and Steinman, 2002; Legge et al., 2002) or Oligonucleotides
by yet unidentified factors. 396.497.1, 5
TCGAATCTTTCAGCCACAGAATGGGCAGTTCATTCA
CTCTAGAATTATTTGCCCCATGTACGCCCGCGTGGATGGGCC3
;Our study proves, without adoptive transfers of DC,
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396.497.2, 5
CATCCACGCGGGCGTACATGGGGCAAATAATTCTAG found green fluorescence in CD11c cells as early as 15 hr after
injection with TAM, and at least until 75 hr after TAM injection. TheAGTGAATGAACTGCCCATTCTGTGGCTGAAAGAT3
. Oligonucleo-
tides were purchased PAGE-purified from Microsynth (9436 Bal- number of CD11cGFP cells in spleen, lymph nodes, and thymus
peaked around 40 hr (data not shown).gach, Switzerland).
Staining with Tetrameric MHC Class I-Peptide Complexes
Tetrameric complexes containing biotinylated H-2Db or -Kb, 2-micro-Mice
globulin, the relevant peptide, and extravidin-PE were generated,C57BL/6 and C57BL/6.PL (Thy1.1) were obtained from the Institut
and staining was performed as described (Altman et al., 1996; Probstfu¨r Labortierkunde, University of Zu¨rich. C57BL/6.PL mice were orig-
et al., 2002).inally obtained from The Jackson Laboratories (Bar Harbor, Maine).
Intracellular Staining for Interferon- (ICS)CD11cCreERT mice express DC-specific, inducible Cre recombinase
Splenocytes were incubated for 6 hr at 37C with 106 M of theas a transgene (see above); ST33.396 mice carry a transgene encod-
specific peptide, with medium alone, or with PMAionomycin in theing LCMV-derived CTL epitopes (GP33-41/Db and NP396-404/Db)
presence of 5 g/ml Brefeldin A. Cells were surface stained withand a -galactosidase-derived CTL epitope (Gal497-505/Kb) as a
anti-CD8-PE (PharMingen) stained intracellularly with anti-mouse-fusion protein with enhanced green fluorescent protein (eGFP). The
IFN-FITC (clone AN18, PharMingen).transgene is separated from its ubiquitous promoter by a loxP-
flanked STOP cassette (see above). DIETER mice are double trans-
Cytotoxicity Assaygenic offspring of (CD11cCreERT X ST33.396) mice. RAGE% mice
Splenocytes were restimulated in vitro for 5 days in the presenceare eGFP-based Cre-indicator mice (Constien et al., 2001). All mice,
of 50 U/ml recombinant mouse IL-2 with irradiated, thioglycollate-except for RAGE%, had a pure C57BL/6 background. To increase
elicited peritoneal macrophages, that were loaded with 108 M ofthe number of available double transgenic (DIETER) mice, we gener-
the relevant peptide. Three-fold dilutions of the cultures were testedated DIETER → C57BL/6 bone marrow chimeras by i.v. injection of
for cytotoxic activity using 51Cr-labeled EL-4 cells that were or wereDIETER bone marrow into lethally irradiated (9.5 Gy from a 57Co-
not loaded with 106 M of the relevant peptides as targets in a 5source) age- and sex-matched C57BL/6 mice. Alternatively, lethally
hr chromium release assay. The percentage of specific lysis wasirradiated C57BL/6 mice were grafted with a 1:1 mixture of bone
calculated as follows: % specific release  (experimental release –marrow from age- and sex-matched DIETER and C57BL/6.PL mice.
spontaneous release)  (maximal release – spontaneous release) Bone marrow chimeras were given Borgal (Hoechst Roussel Vet,
100%.Lyssach, Switzerland) in the drinking water (1 mg/ml Sulfadoxin, 0.2
mg/ml Trimethoprim) during the first 2 weeks after reconstitution,
Protection Assayand left at least for 8 weeks before use in experiments. Initial experi-
Mice were infected i.v. with 100 pfu LCMV-Armstrong, and spleensments showed that DIETER bone marrow chimeras and DIETER
were removed 4 days later and were homogenized. Ten-fold serialmice were indistinguishable in the outcome of all types of experi-
dilutions of spleen homogenate were used to infect monolayers ofments described. Most experiments shown here were performed
MC57G fibroblasts for 48 hr. LCMV was detected using the LCMV-with DIETER bone marrow chimeras.
NP-specific antibody VL-4 as described (Battegay et al., 1991).All animal experiments were performed in Switzerland or in Greece
according to respective national laws on animal protection.
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